Because of their special optical and electrochemical characteristics, superior biocompatibility, adjustable surface chemistry, and inexpensive, scalable synthesis, carbon dots (CDs), including carbon quantum dots and graphene quantum dots, have become powerful and adaptable nanomaterials for advanced pharmaceutical analysis and other toxicants. The sensitive and selective detection of active pharmaceutical substances, degradation products, contaminants, biomarkers, and therapeutic medication levels in complex matrices has shown great promise in recent years with CD-based nanobiosensors. The development of various sensing platforms, such as electrochemical, optical, and dual-mode biosensors, as well as integration into microfluidic, paper-based, and wearable point-of-care (POC) devices, is made possible by their intrinsic fluorescence, effective electron transfer capacity, and ease of functionalization. With an emphasis on sensing mechanisms, biorecognition techniques, and analytical performance, this study critically reviews current developments in CD-based nanobio/chemosensors for pharmaceutical analysis. It includes a thorough discussion of important applications in drug development, stability research, therapeutic drug monitoring, and drug quality control. Along with new developments like green synthesis, AI-assisted signal processing, and smart sensing platforms, current issues with reproducibility, standardization, biocompatibility, and regulatory validation are highlighted. Lastly, prospects for the industrial application and clinical translation of CD-based nanobiosensors are discussed.

Because of their special optical and electrochemical characteristics, superior biocompatibility, adjustable surface chemistry, and inexpensive, scalable synthesis, carbon dots (CDs), including carbon quantum dots and graphene quantum dots, have become powerful and adaptable nanomaterials for advanced pharmaceutical analysis and other toxicants. The sensitive and selective detection of active pharmaceutical substances, degradation products, contaminants, biomarkers, and therapeutic medication levels in complex matrices has shown great promise in recent years with carbon dot-based nanobiosensors. The development of various sensing platforms, such as electrochemical, optical, and dual-mode biosensors, as well as integration into microfluidic, paper-based, and wearable point-of-care devices, are made possible by their intrinsic fluorescence, effective electron transfer capacity, and ease of functionalization. With an emphasis on sensing mechanisms, biorecognition techniques, and analytical performance, this study critically reviews current developments in carbon dot-based nanobiosensors for pharmaceutical analysis. It includes a thorough discussion of important applications in drug development, stability research, therapeutic drug monitoring, and drug quality control. Along with new developments like green synthesis, AI-assisted signal processing, and smart sensing platforms, current issues with reproducibility, standardization, biocompatibility, and regulatory validation are highlighted. Lastly, prospects for the industrial application and clinical translation of carbon dot-based nanobiosensors are discussed.